Market Wire - Actavis receives approval of generic Wellbutrin XL(R) 300mg in the United States
Reykjavik, Iceland, 19 August 2008 -
- Actavis Group, the international generic pharmaceuticals company, today
announced that
it has received approval from the US Food & Drug Administration to
market Bupropion Hydrochloride extended-release tablets (XL) 300mg.
Distribution of the product will commence immediately.
Bupropion Hydrochloride extended-release tablets (XL), available in
300mg strength, are the generic equivalent of Wellbutrin XL for the
treatment of major depressive disorder. Annual US sales of brand and
generic Wellbutrin XL 300mg were US$581 million for the 12 months
ending June 2008 according to IMS Health data.
Commenting on the new approval, Douglas Boothe, Chief Executive
Officer of Actavis, Inc. in the United States said:
“Bupropion XL compliments our existing Bupropion SR offerings and
expands the dosage options for our customers and patients. This
approval also highlights Actavis Group’s focus and expertise in
bringing complex controlled-release technologies to the marketplace.”
About Actavis
Actavis is one of the world’s leading generic pharmaceutical
companies specializing in the development, manufacture and sale of
generic pharmaceuticals. With headquarters in Iceland, Actavis has
operations in 40 countries, with 11,000 employees. The United States
is the company’s single largest market. Actavis’ US operations are
located in New Jersey, Maryland, North Carolina and Florida.
More information about Actavis Group can be found at www.actavis.com
Inquiries
David Myers, Jr.
Manager, Products & Communications
Tel: (973)993-4503
E-mail: dmyers@actavis.com
Hjordis Arnadottir
Corporate Communications
Tel: (354) 535 2300
E-mail: harnadottir@actavis.com
Any statements contained in this press release that refer to Actavis’
estimated or anticipated future results or future activities are
forward-looking statements which reflect the Company’s current
analysis of existing trends, information and plans. These
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially
depending on factors such as the availability of resources, the
timing and effect of regulatory actions, the success of new products,
the strength of competition, the success of research and development
issues, unexpected contract breaches or terminations, exposure to
product liability and other lawsuits, the effect of currency
fluctuations and other factors.
Copyright Hugin AS 2008. All rights reserved.
